Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYEGUARD-X: Open-label extension safety study of gevokizumab in chronic non-infectious uveitis
2013-004973-29Phase 3Terminated
- Sponsor
- Servier
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gevokizumab in chronic non-infectious uveitis and Hyalitis, sponsored by Servier. Primary endpoint: Safety endpoints. Started Jul 2014; status: terminated.
02
Drugs
gevokizumab
03
Conditions
chronic non-infectious uveitisHyalitis
Beyond the preview
Go deeper on 2013-004973-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004973-29.